



Vaccines and Global Health: The Week in Review
15 November 2025 :: Issue 822
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Measles

PAHO calls for regional action as the Americas lose measles elimination status

Washington, D.C., 10 November 2025 (PAHO) –The Pan American Health Organization (PAHO) announced today that the Region of the Americas has lost its verification as free from endemic measles transmission.

The decision follows the conclusion of the PAHO Measles, Rubella, and Congenital Rubella Syndrome Elimination Regional Monitoring and Re-Verification Commission, which met in Mexico City from 4 to 7 November 2025 to review the epidemiological situation across the region. The Director of PAHO, Dr. Jarbas Barbosa, received and agreed with the Commission’s report indicating that endemic transmission of measles has been reestablished in Canada, where the virus has circulated for at least 12 months.

As a result, the Americas, which was the first region in the world to eliminate measles twice, has now lost its measles-free status. All other countries continue to maintain their measles elimination status.

“This loss represents a setback—but it is also reversible,” said Dr. Barbosa, “Until measles is eliminated worldwide, our Region will continue to face the risk of reintroduction and spread of the virus among unvaccinated or under-vaccinated populations. However, as we have demonstrated before, with political commitment, regional cooperation, and sustained vaccination, the Region can once again interrupt transmission and reclaim this collective achievement.”..

PAHO’s response and recommendations

PAHO continues to provide technical support to countries to strengthen surveillance, laboratory diagnosis, outbreak response, and vaccination campaigns. Experts have been deployed to Mexico, Argentina, and Bolivia, and the organization is monitoring risks in Belize, Brazil and Paraguay.,,

RVC strongly encourages countries to:

- Continue strengthening surveillance, immunization and outbreak rapid response activities for every suspect case.
- Expand and consolidate electronic immunization registries across all countries, following PAHO’s established guidelines.
- Maintain sustainable laboratory surveillance by allocating sufficient financial and human resources.
- For suspected cases with clinical and epidemiological risk factors and a negative measles IgM result (with specimens collected within 0–3 days after rash onset), perform PCR testing to confirm or rule out infection.
- Implement all recommendations down to the local level.
- Document outbreak closure following the Regional Framework guidelines....

.....
.....

Health at a Glance 2025 - OECD Indicators

OECD 13 November 2025 :: 244 pages

Health at a Glance provides a comprehensive set of indicators on population health and health system performance across OECD Members, Key Partners and accession candidate countries. These indicators cover health status, non-medical determinants and health risk factors, access to and quality of healthcare, health spending and health system resources. Analysis draws from the latest comparable official national statistics and other sources.

Alongside indicator-by-indicator analysis, an overview chapter summarises the comparative performance of countries and major trends. This edition also includes a thematic chapter on gender and health.


[Excerpt]

...Routine vaccinations

Vaccination is one of the most effective public health interventions, offering substantial health and economic benefits by protecting against infectious diseases. Childhood vaccination against infectious diseases, such as diphtheria, tetanus and pertussis (DTP), measles and hepatitis B, has dramatically reduced morbidity and mortality worldwide. For older adults, who are at greater risk from influenza, vaccines provide critical protection, reducing severe illness, hospitalisations, and mortality, and mitigating seasonal pressures on health systems. High national coverage rates, however, may not be sufficient to stop disease spreading if vaccination rates are uneven across regions or among specific population groups. Hence, government action to ensure access to vaccines and garner trust and public confidence in the safety and efficacy of vaccination across all population groups is essential for the success of vaccination programmes.

Figure 6.1 shows vaccination coverage for DTP and measles. Across OECD countries, an average of 89% of children received the recommended measles vaccinations in 2024. Continued gaps in coverage of measles vaccine in specific population groups, including in countries with high coverage at the national level, are propelling outbreaks – measles incidence has reached its highest levels in recent decades in Europe (UNICEF/WHO, 2025[1]) – as well as increasing substantially in North and South America (WHO, 2025[2]). **Public perceptions of the importance of vaccines for children declined during the COVID-19 pandemic in most OECD countries.**

Figure 6.1. Percentage of eligible children who have received two doses of a measles-containing vaccine and three doses of the diphtheria, tetanus and pertussis vaccine, 2024 (or nearest year)



1. Data refer to estimates. Dotted lines indicate WHO minimum targets of 95% for measles and 90% for DTP. * Accession/partner country.
Source: OECD Health Statistics 2025.


In 2024, only six OECD countries reached the minimum measles immunisation (two doses) level recommended by the World Health Organization (WHO) of 95% population coverage. Rates of immunisation for measles, which is often incorporated with rubella and/or mumps vaccination, were particularly low in Mexico (69%), Chile (73%) and Estonia (74%). **Compared to pre-pandemic levels in 2019, measles vaccination rates have decreased on average in OECD countries by nearly 2 percentage points (p.p.)**

The decrease was particularly substantial in Chile (-18 p.p.), Estonia and Costa Rica (-15 p.p.), as well as in Poland, Lithuania, the Netherlands, Canada and OECD accession/partner countries Argentina and Romania, with drops of 8 p.p. or more.

Across OECD countries, an average of 93% of children received the recommended DTP vaccinations in 2024. However, more than one in five OECD countries did not meet the minimum immunisation level recommended by WHO for DTP (90%) in 2024, with particularly low rates in Mexico (78%) and Estonia (81%). OECD accession/partner countries including South Africa, Argentina, Romania, Peru and Indonesia also all had coverage of 80% or lower. Children's vaccination rates for DTP declined slightly on average (by less than 2 p.p.) between 2019 and 2024 in OECD countries, although Estonia and Czechia, as well as OECD accession/partner countries Indonesia and South Africa, had more substantial drops (-10 p.p. or more).

Influenza is a common seasonal infectious disease, which leads to 3-5 million severe cases worldwide each year, along with an estimated 650 000 deaths (WHO, 2019[3]). Annual vaccination is recommended for high-risk groups, including adults aged 65 and older. **Figure 6.2 shows that the WHO's target influenza immunisation rate of 75% was only attained in Korea (85%), Mexico (83%), the United Kingdom and Denmark (78%) in 2023.** Coverage was below 20% in Poland, Türkiye, the Slovak Republic, Latvia, Slovenia and Hungary, as well as OECD accession country Bulgaria.


Figure 6.2. Percentage of population aged 65 and over vaccinated against influenza, 2024 and 2019 (or nearest year)



Note: Belgium's data exclude people in nursing homes. The Slovak Republic's data cover people aged 59+. 1. Latest data from 2023. 2. Latest data from 2022.

* Accession/partner country.

Source: OECD Health Statistics 2025.

StatLink  <https://stat.link/2u9381>

Influenza vaccination rates for people aged 65 and over have increased over time, reaching 51% on average across OECD countries in 2024, from 46% in 2019. This reflects expansion of influenza vaccination campaigns and increased awareness. Still, coverage is lower than the high of 55% reached in 2021, which was facilitated by increased awareness of vaccination, and by the practice of co-

administration of COVID-19 and influenza vaccines that increased access and convenience. Compared to 2019, increases were above 20 p.p. in Denmark and Norway. However, some countries had declines of more than 5 p.p., including Ireland, Israel and Hungary and OECD accession country Croatia.

Definition and comparability

Childhood vaccination refers to eligible children who have received the 2nd dose of measles-containing vaccine and three doses of combined diphtheria, tetanus and pertussis vaccine in a given year. These indicators are based on the vaccination policy in each country. The age of complete immunisation differs across countries, owing to different immunisation schedules.

Influenza vaccination rates refer to the number of people aged 65 and over who have received an annual influenza vaccination, divided by the total number of people aged over 65. In some countries, the data are for people aged over 60. Unless otherwise stated, the data shown for 2024 refer to the calendar year 2024 or to the flu season 2024/25.

References

[1] UNICEF/WHO (2025), European Region reports highest number of measles cases in more than 25 years, <https://www.unicef.org/press-releases/european-region-reports-highest-number-measles-cases-more-25-years-unicefwho-europe>

[2] WHO (2025), Measles – Region of the Americas, <https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON565>

[3] WHO (2019), Global Influenza Strategy 2019-2030, World Health Organization, <https://apps.who.int/iris/handle/10665/311184>

.....
.....

Pandemic Financing

High Level Independent Panel Calls for Urgent Action from G20 and Other Nations to Close the Global Pandemic Financing Gap

November 11, 2025

...the world remains dangerously underprepared for future pandemics and must take urgent, coordinated action to accelerate financing for sustainable and equitable pandemic prevention, preparedness, and response (PPR).

In its new report, *Closing the Deal: Financing Our Security Against Pandemic Threats*, the Panel issues five recommendations for practical and bold action to take pandemic threats off the table and warns of compounding risks: **global health financing is eroding just as the threats of pandemic and deliberate biological events are rising.**

"Pandemic preparedness stands at a precipice," said Victor J. Dzau, Panel Co-Chair and President of the US National Academy of Medicine (Panel Secretariat). "The world has become distracted from preparing for the next pandemic, even as biological risks multiply. Our collective ability to prevent and respond to health emergencies remains dangerously insufficient."...

The Panel's report identifies five growing financing gaps for global pandemic PPR:

1. **Domestic resource mobilization and non-ODA financing.** Pandemic PPR remains severely under-financed. Countries are not tracking or investing sufficiently in PPR through national budgets. Security and private sector financing remain elusive, and financing for PPR in high-risk fragile settings, often beyond the reach of government systems, is inadequate.
2. **Medical countermeasure (MCM) access and surge manufacturing.** Production is not sufficient and remains geographically concentrated and dependent on donor funding.

3. **Development bank incentives.** Low- and middle-income countries must be able to act early and procure MCMs when threats emerge. Multilateral development banks (MDBs) lack clear at-risk financing mechanisms for rapid pandemic response, and approved products wait too long for pre-qualification.
4. **Tests, treatments, and personal protective equipment (PPE).** Innovation and manufacturing remain underfunded and fragmented, yet these products are crucial in the earliest days of a crisis.
5. **The Pandemic Fund.** The Fund is still not sustainably capitalized or operating at scale, yet its regional, country-led and collaborative model is fit for purpose in the current aid landscape.

...To address financing gaps, the report presents **five operational recommendations** designed for implementation by or before the September 2026 United Nations (UN) High-Level Meeting (HLM) on Pandemic Prevention, Preparedness, and Response.

1. **Increase domestic investment and non-ODA incentives. Rigorously track pandemic financing.** At the UN HLM, governments should announce their intention to meet minimum benchmarks for pandemic financing across health and security budgets, linked to prioritized, costed national plans. MDBs and international finance institutions should better align and directly finance civil society organizations and regional institutions in fragile settings. The G20 Joint Finance and Health Task Force should launch an annual Global Pandemic Spending Tracker to hold countries accountable, and to monitor national and private-sector spending across health, security, and development budgets toward the benchmarks below.
2. **Accelerate geographically diversified access to MCMs.** The International Finance Corporation and other development finance institutions should establish at least one dedicated MCM surge financing facility with a “standby” roster of regional manufacturers and pooled procurement mechanisms. Philanthropies should support an associated operational platform for technical assistance, market assessments, and stress testing, to expand the list of regional manufacturers, particularly for under-invested products.
3. **Enable at-risk financing for MCMs by development banks.** All MDBs and relevant public development banks should establish and clearly communicate mechanisms for borrowing at-risk to allow countries to purchase promising candidate medical countermeasures before regulatory approval—accelerating access and saving lives. At the same time, the World Health Organization (WHO) and national regulators must accelerate pre-qualification or temporary authorizations for products already approved by WHO-Listed Authorities at Maturity Level 3 or higher.
4. **Operationalize Financing for Tests, Treatments, and PPE.** The world needs designated regional and global anchor institutions and a financing strategy to coordinate innovation, manufacturing, and scale-up for these products, which are critical when crises emerge, yet chronically underprioritized. This includes at least one PPE manufacturing hub per region with regional stockpiles for essential long-shelf-life products.
5. **Strengthen and cement the Pandemic Fund as the world’s premier facility for external support for preparedness financing.** The World Bank, regional development banks, and public development banks should commit to using their tools and a standing allocation to ensure renewable support for the Fund and its work. The Fund should double down on its core preparedness mandate as well as its role in tackling cross-border threats, catalyzing domestic and non-ODA resources, enhancing access for civil society implementers in fragile settings, and partnering more systematically with MDBs to leverage their lending.

In addition, the High-Level Independent Panel calls for **Minimum Benchmarks for Pandemic PPR Financing: Governments should allocate, at a minimum, at least 0.1 to 0.2 percent of gross domestic product per year, per country directed toward pandemic PPR spending.** This should be complemented by at least 0.5 to 1.0 percent of security and defense budgets per year from G20 and other high- and upper-middle income countries, directed toward biosecurity, biosurveillance, and the 100 Days Mission to support deterrence, operational resilience, and to prevent deliberate and accidental misuse of biological agents at home and globally. The Panel underscores the 2021






benchmark for leaders to invest at least \$15 billion annually in international financing toward regional and global public goods to fight cross-border threats. To achieve these goals in 2026, decisive and sustained international leadership is required. The Panel is committed to working with the G20 and all other relevant actors to bring these recommendations into reality in advance of next year’s UN HLM...

.....
.....

Gaza/oPT

Public Health Situation Analysis - oPt

12 November 2025

Hostilities in the occupied Palestinian territory (oPt)				Date: 11 November 2025
Public Health Situation Analysis (PHSA)				
This is the eleventh PHSA produced by WHO on the crisis in oPt since October 2023.				
Typologies of emergency	Main health threats	WHO grade	Security level (UNDSS) ¹	INFORM (2025) ²
 Conflict	Trauma and Injury (including rehabilitation)	G3	Gaza Strip: (High- Level 5) West Bank: (Substantial- Level 4)	INFORM Risk: 6.4/ 10 (High) Global Risk Ranking: 21 out of 191 countries
 Nutrition	Malnutrition			
 Food security	Acute Diarrhoeal Illness			
 Displacement	Acute Respiratory Infections			
 Epidemics	Tuberculosis			
	Noncommunicable Diseases			
	Cardiovascular Diseases			
	Maternal and Neo-natal Health			
	Mental Health Conditions			
	Poliomyelitis (cVDPV2)			
	Anti-Microbial Resistance (AMR)			

[Excerpts referencing vaccination]
[p.9]

...**Vaccination coverage before the current escalation:** Vaccination coverage for registered refugee children has been close to 100% for more than a decade.¹²³ Child vaccination has seen substantial investments in recent years, particularly through a vaccine forecast for 2020–2022 developed in cooperation with the United Nations to secure needed vaccines.¹²⁴ The COVID-19 response generated significant investments in public health infrastructure and vaccines.¹²⁵ 10

However, routine vaccination has been interrupted with the escalation of violence. **The impact of the vaccination system breakdown has become apparent with the reemergence of vaccine preventable diseases (VPDs), including with the recent outbreak of poliovirus type 2 (cVDPV2), after 25 years of being polio-free.**¹²⁶

Most recently, the full blockade has also had a detrimental impact on the provision of health services, including for children. Children are now unable to get their routine vaccinations, reported UNICEF.

Moreover, the Polio Technical Committee reported that the fourth round of the **polio vaccination campaign targeting** over 600 000 children, which was scheduled to take place in early April, is still currently pending due to ongoing displacement orders, movement restrictions, and denial of vaccine and essential supply entry into Gaza. 127

VACCINATION COVERAGE DATA	Year ¹²⁸	Gaza Strip	West Bank	Year ¹²⁹ estimates	oPt ¹³⁰
DTP-containing vaccine, 1st dose	2022	104.1 %	99.9 %	2023	88%
DTP-containing vaccine, 3rd dose	2022	102 %	95 %	2023	88%
Polio, 3 rd dose	2022	103 %	102 %	2023	89%
Measles-containing vaccine, 1st dose	2022	101.9 %	98.4 %	2023	89%

Vaccination Coverage During Current Escalation: On 6 November 2025, it was announced that UNICEF, UNRWA, WHO and partners, in collaboration with the Ministry of Health, would launch an integrated catch-up campaign for routine immunization, nutrition, and growth monitoring in the Gaza Strip to reach 44 000 children cut off from essential life-saving services by two years of conflict.¹³¹ The campaign will be implemented in three rounds to reach children with three doses of Pentavalent, Polio, Rota & Pneumococcal Conjugate Vaccine and two dose of Measles, Mumps, Rubella vaccine. The first round of the campaign will take place from 9 to 18 November.¹³²

It is estimated that 1 in 5 children under three years of age are either zero-dose or have missed vaccinations because of the conflict, putting them at risk of vaccine-preventable disease outbreaks. The catch-up campaign aims to provide these children with routine childhood vaccines that protect against measles, mumps, and rubella, diphtheria, tetanus, pertussis, hepatitis B, tuberculosis, polio, rotavirus and pneumonia.¹³³...

[p.19]

...Poliomyelitis (cVDPV2)

There is an on-going urgent response to prevent the spread of polio after circulating variant poliovirus type 2 (cVDPV2) was detected in Gaza, after 25 years of being polio-free.²⁶¹ Around 90% of children under 10 in the Gaza Strip have received a dose of the polio vaccine following the three rounds of an emergency vaccination campaign conducted by partners in early September, November 2024 and February 2025.²⁶²

Three new AFP cases were reported in W41, bringing the total to 54 cases for 2025. Stool samples were collected and awaiting shipment for laboratory testing. October ES samples were collected from Deir Al-Balah (Al-Bassa & Al-Berka), Khan Younis.²⁶³ No cVDPV2 has been detected in ES samples in the past 6 months of enhanced surveillance.

Anti-Microbial Resistance (AMR)

In war-affected regions, where healthcare systems are already compromised, AMR presents a greater threat. Significant gaps in the regulation of antibiotic prescription, dispensation, and consumption have been reported in Gaza.²⁶⁴

Cholera

While epidemic cholera is not currently found in Gaza, multiple surrounding countries have experienced recent or ongoing cholera outbreaks.²⁶⁵ With the poor WASH situation and the potential for a large increase in international movement of aid workers, IDF soldiers, international contractors, international peacekeeping troops, and Gazans returning from abroad with the start of a ceasefire- Gaza is at high risk of importation and if there is an introduction event a large outbreak is almost certain...

Measles

No confirmed cases of measles have been reported in Gaza between October 2023 and October 2025. Measles is among the most highly infectious diseases known and is symptomatic in nearly 100% of exposed, non-immune individuals. High population density, inadequate shelter, poor sanitation, and undernutrition are all major risk factors for infection, severity, and death, and all are features of the deplorable conditions for those people living in Gaza.

Although the Gaza Strip has maintained an overall high administrative coverage for measles-containing vaccine with a median coverage of 97% between 2009 and 2018, the continuous socio-economic decline conflict and disruptions to services have challenged the health sector.²⁷² As the current coverage rate of immunizations for those under the age of 3 is currently unknown and there have been documented disruptions to the EPI program, the risk of non-immune sub-populations is high. In addition, the risk of importation of measles from international movement is also high.

Typhoid

Typhoid is a life-threatening infection caused by the bacterium *Salmonella Typhi*.²⁷³ Notably between 1 and 6% of people infected with the strain become chronic, asymptomatic carriers, which is huge threat to public health.²⁷⁴ In 2022, Gaza reported 20 cases per 100 000 populations, and 13 cases per 100 000 populations from the West Bank.²⁷⁵ There is currently no diagnostic testing available.

Meningococcal disease

A total of 1375 suspected meningitis cases have been reported since May, with a noticeable decline in trend over the past four EPI weeks. Of these, 74% were probable viral meningitis, while 26% were probable bacterial meningitis. The surveillance team is following up with hospital focal points to determine the outcomes of bacterial meningitis cases.²⁸²

Chicken Pox

As of 30 June 2024, there were 11 214 cases of chickenpox reported. ²⁸³ More recent figures are not available. However, large outbreaks have been clinically diagnosed in multiple settings of overcrowded shelters.

Mumps

Mumps is endemic in Gaza, with over 590 suspect cases being reported since October 2023.²⁸⁴ The MoH reported 7/100,000 population cases in 2022. Mumps cases peak in the winter months, There is currently no diagnostic testing available.

West Nile Fever (WNF)

WNF will be less of a risk to vulnerable populations during winter months as mosquitoes are less active in cooler weather.

Dengue Fever

Dengue fever will be less of a risk to vulnerable populations during winter months as mosquitoes are less active in cooler weather.

Hepatitis E

To date, there have been no suspected cases of Hepatitis E.

Hepatitis B

When medical needs are unmet for viral hepatitis, it can lead to serious infections, including hepatitis B.²⁸⁵ In Gaza, according to the MoH Annual Report, in 2022 there were 146 known cases of Hepatitis B. Concern is present as there is a lack of testing capacity for both dialysis and blood transfusion.

Hepatitis C

While cases of hepatitis C have also been confirmed in various areas of the Gaza Strip, knowledge of the severity of its spread and precise number of infections is hindered by the inability to conduct necessary medical tests in local hospitals and need to send samples abroad.²⁸⁶ In Gaza, in 2022 there were zero cases of Hepatitis C.²⁸⁷ Access to water and to safe sanitation facilities is essential for women and girls managing their menstrual hygiene. When those needs are unmet it can lead to serious infections.²⁸⁸ Concern is present as there is a lack of testing capacity for both dialysis and blood transfusion.

Diphtheria

Gaza has maintained a high administrative coverage for diphtheria, however the current overcrowding, poor hygiene and sanitary living conditions and disruption to health services including routine vaccination can facilitate the spread of Diphtheria, especially in settings with limited access to clean water and sanitation. 22

HIV/AIDS

Analysis based on Palestinian Ministry of Health records reveals a cumulative case load of only 98 reported instances of HIV infection between 1988 and 2017, with male youth disproportionately affected.²⁸⁹ The lack of systematic HIV surveillance in Palestine means that these figures likely underestimate the true scale of HIV and associated risks.²⁹⁰ A major challenge lies in overcoming the social and cultural barriers that impede assessment of and response to HIV vulnerability in groups at high risk. ²⁹¹ The forcible displacement of people through conflict or disaster is associated with disruption of care and treatment for people already living with HIV.²⁹² Further information is urgently needed to better understand the determinants of the HIV epidemic across the oPt.²⁹³ Lack of screening tests for dialysis and blood transfusion present a possible risk...

.....

[UNICEF says Israel blocking one million syringes needed to vaccinate Gaza children](#)

By [Olivia Le Poidevin](#)

Reuters, November 11, 2023:27 PM EST Updated 18 hours ago

GENEVA, Nov 11 (Reuters) - UNICEF said on Tuesday essential items including syringes to vaccinate children and bottles for baby formula are being denied entry into Gaza by Israel, preventing aid agencies from reaching those in need in the war-devastated territory.

As UNICEF undertakes a mass children's vaccination campaign with a fragile ceasefire in place, it said it faces serious challenges getting 1.6 million syringes and solar-powered fridges to store vaccine vials into Gaza. The syringes have awaited customs clearance since August, UNICEF said.

"Both the syringes and the ... refrigerators are considered dual-use by Israel and these items we're finding very hard to get them through clearances and inspections, yet they are urgent," UNICEF spokesperson Ricardo Pires said...

Hundreds of trucks carrying food, water, fuel, gas, medicines, medical equipment, tents, and shelter supplies enter the Gaza Strip every day, COGAT said, in close coordination with the U.N.

UNICEF launched the first of three rounds of catch-up immunisations on Sunday to reach over 40,000 children under three who missed routine vaccines against polio, measles and pneumonia, following two years of [war](#) in Gaza.

On the first day of the campaign it reached over 2,400 children with multiple vaccines.

"The vaccination campaign has started, but we have two rounds to go, and for that we need more supplies," Pires said...

.....
.....
.....

Polio – PHEIC

Polio this week [05 November 2025]

Headlines

:: WPV1 is detected in environmental sample in Germany

Wild poliovirus type 1 (WPV1) was isolated from an environmental sample in Hamburg, Germany, linked to WPV1 last identified in Kandahar, Afghanistan in August. No associated cases of paralysis have been detected in Germany. GPEI partners are working closely with national and local public health authorities, through the WHO Regional Office for Europe, to support ongoing investigations, assess potential risks, and determine whether any additional public-health measures are needed. Germany has strong routine immunization coverage and a robust environmental surveillance system — which enabled this virus to be detected in the absence of any cases of disease. This early detection provides the opportunity to implement appropriate measures swiftly to protect children and communities. This positive isolate will be officially reflected in next week's global update. [More](#).

:: EMRO Polio Director Hamid Jafari retires

After more than three decades of service to public health, [Dr Hamid Jafari](#), Director of Polio Eradication and Vaccine-Preventable Diseases in WHO's Eastern Mediterranean Region, is retiring, leaving a legacy of leadership, integrity and humanity that has shaped immunization and polio eradication efforts worldwide. From Karachi to Atlanta, Alexandria, Delhi, Geneva and finally Amman—where he concludes his WHO career—Dr Hamid's story spans continents and decades, marked by resilience and an unshakable belief in the power of public health to change lives. The GPEI extends our profound gratitude to Dr Jafari for his tireless work, leadership and inspiration, and we wish him all the very best for a more-than well-deserved retirement. We will miss you, Hamid – thank you for everything!

WPRO marks 25 years since certification

Dr Saia Ma'u Piukala, WHO Regional Director for the Western Pacific: "We are celebrating a remarkable milestone: 25 years since WPRO was certified free of indigenous wild poliovirus. But while we celebrate, we cannot be complacent. Polio is entirely preventable – yet it resurfaces when vigilance falters. We must continue to vaccinate every child, everywhere. Not only against polio, but against all vaccine-preventable diseases." [More](#).

Summary of new polioviruses this week:

- :: Chad: two cVDPV2 cases
- :: Germany: five cVDPV2-positive environmental samples
- :: Nigeria: five cVDPV2 cases
- :: United Kingdom: one cVDPV2-positive environmental sample

.....

Statement of the Forty-third meeting of the Polio IHR Emergency Committee

11 November 2025 *Statement*

[Excerpts]

The 43rd meeting of the Emergency Committee under the International Health Regulations (IHR or Regulations) on the international spread of poliovirus was **convened by the WHO Director-General on 01 October 2025** with eight out of nine Committee members and the adviser meeting via video

conference with affected countries, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global target of interruption and certification of WPV1 eradication by 2027 and interruption and certification of cVDPV2 elimination by 2029. Technical updates were received about the situation in the following countries: Benin, Cameroon, Chad, Germany, Israel, and Pakistan. The Committee reviewed detailed written updates on the situation in Afghanistan.

Amendments to the IHR, adopted by the Seventy-seventh World Health Assembly, through resolution WHA77.17 in June 2024, entered into force on 19 September 2025 for 182 of 196 States Parties.[1] The 43rd meeting of the IHR Emergency Committee on polioviruses, held on 01 October 2025, was the first under the amended Regulations. **Key amendments to the IHR include, *inter alia*, broader poliovirus notification requirements; the introduction of the determination of “pandemic emergency”[2], a higher level of global public health alert with respect to a public health emergency of international concern (PHEIC);** measures to strengthen equitable access to relevant health products; and recognition of health documents in non-digital and digital formats...

...Conclusion

1. **The Committee unanimously concluded that the risk of international spread of poliovirus continues to constitute a *Public Health Emergency of International Concern (PHEIC)*** and recommended extending the Temporary Recommendations for a further three months.
2. The Committee, after a thorough review of the epidemiological and programmatic situation, unanimously concluded that **the event does not constitute a *pandemic emergency*.**

...Additional considerations and recommendations

The Committee noted that the Global Polio Eradication Initiative (GPEI) has developed an **Action Plan** aimed at sustaining and enhancing programme operations to achieve the goals of the GPEI Strategy, within the limits of available resources. The Committee appreciated the comprehensive and consultative process undertaken by the GPEI in formulating the plan. **However, the Committee expressed concern that the current financial shortfall, estimated at nearly 30%, poses a significant risk to all components of the programme, including the ability to maintain sensitive poliovirus surveillance.**

These risks are further compounded by concurrent funding constraints across WHO, international partners, and national governments, reflecting wider fiscal pressures across the global health landscape. The Committee therefore urged donor countries and partner organizations to strengthen their financial support, emphasizing that the consequences of underfunding could be substantial and far-reaching. **The Committee also called on national governments to prioritize polio eradication within their domestic frame mechanisms** to safeguard the gains made and sustain progress toward global eradication...

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, **the Director-General accepted the Committee’s assessment, and on 10 November 2025 determined that the poliovirus situation continues to constitute a public health emergency of international concern (PHEIC) with respect to WPV1 and cVDPV. The poliovirus situation, however, does not constitute a pandemic emergency.**

The Director-General endorsed the Committee’s recommendations for countries meeting the definition for ‘States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread’, ‘States infected with cVDPV2 with potential risk for international spread’ and for ‘States previously infected by

WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective, 10 November 2025.

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)
:: [Think Tanks](#)
:: [Public Consultations/Call for Inputs/Call for Papers](#)

.....

.....

WHO & Regional Offices [15 Nov 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

14 November 2025 News release

[WHO and Brazil urge swift action on Belém Health Action Plan at COP30](#)

14 November 2025 Departmental update

[Investing in primary health care in Ethiopia: a joint technical workshop](#)

14 November 2025 Departmental update

[Collaboration for greater impact - PHA4GE Conference and IPSN Global Partners Forum 2025](#)

12 November 2025 News release

[Global gains in tuberculosis response endangered by funding challenges](#)

12 November 2025 News release

[Egypt becomes the seventh country in the Eastern Mediterranean Region to eliminate trachoma as a public health problem](#)

11 November 2025 Departmental update

[World Pneumonia Day – 12 November 2025](#)

11 November 2025 Statement

[Statement of the Forty-third meeting of the Polio IHR Emergency Committee](#)

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 14 November 2025

Ethiopia confirms first outbreak of Marburg virus disease

:: 14 November 2025

Prevention as the first line of defence against Ebola

WHO Region of the Americas PAHO

:: 13 Nov 2025

COP30: PAHO Director call countries to implement the Belém Health Action Plan to build more resilient, inclusive health systems

For COP30's Health Day, Dr. Barbosa highlighted the importance of social participation and innovation to help health systems adapt to environmental challenges. Belém, Brazil, November 13, 2025 (PAHO)— The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, celebrated the launch of the Belem Action Plan For The Adaptation Of...

:: 10 Nov 2025

PAHO calls for regional action as the Americas lose measles elimination status

Washington, D.C., 10 November 2025 (PAHO) –The Pan American Health Organization (PAHO) announced today that the Region of the Americas has lost its verification as free from endemic measles transmission. The decision follows the conclusion of the PAHO Measles, Rubella, and Congenital Rubella Syndrome Elimination Regional Monitoring and Re...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 13 November 2025 *Media release*

One in 7 children and adolescents in the WHO European Region lives with a mental health condition, finds new WHO/Europe report

:: 13 November 2025 *Media release*

Detection of wild poliovirus type 1 in environmental sample in Germany

WHO Eastern Mediterranean Region EMRO

:: **Families returning home join Syria's Big Catch-Up to protect every child**

13 November 2025

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

12 November 2025

Public Health Situation Analysis - oPt

.....

Disease Outbreak News (DONs)

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
No new digest content identified.*

.....

Weekly Epidemiological Record

Vol. 100, No. 46, pp. 553–566 14 November 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Suriname and Timor-Leste certified as malaria-free

:: Schistosomiasis and soil-transmitted helminthiasis: progress report, 2024

.....

New WHO Publications

<https://www.who.int/publications>

Selected

14 November 2025

[**Paediatric drug optimization for malaria: meeting report, 24-26 June 2025**](#)

14 November 2025

[**Priority setting in tuberculosis programme planning: policy brief**](#)

14 November 2025

[**Sixteenth Meeting of the WHO South-East Asia Regional Immunization Technical Advisory Group**](#)

12 November 2025

[**Global tuberculosis report 2025**](#)

Overview

The WHO Global tuberculosis report 2025 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2025 edition of the report is based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2025, 184 countries and areas (out of 215) with more than 99% of the world's population and TB cases reported data.

Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in this global TB report.

.....

.....

.....

Africa

Africa CDC [15 Nov 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

[**Africa CDC Statement on Confirmed Marburg Virus Disease in Jinka, Southern Region, Ethiopia**](#)

Addis Ababa, Ethiopia, 15 November 2025 — The Africa Centres for Disease Control and Prevention (Africa CDC) acknowledges the confirmation by the Federal Ministry of Health of Ethiopia and the Ethiopian Public Health Institute (EPHI) of an outbreak of Marburg virus disease (MVD) in Jinka, Southern Region.

Press Releases

[Africa CDC Launches Operational Research on Malaria in Southern Africa](#)

Lusaka, Zambia | 12 November 2025 — The Africa Centres for Disease Control and Prevention (Africa CDC) has launched operational research on malaria in Lesotho, Namibia and Zimbabwe, supported by a US\$150,000 grant from the World Bank.

This initiative, which follows recurring malaria outbreaks in the southern region, will be conducted from 14 November to 12 December 2025, and aims to strengthen Member States' efforts to control and eliminate malaria...

.....
.....

China – CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [15 Nov 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [15 Nov 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-11-14 / No. 46 WORLD ANTIBIOTIC AWARENESS WEEK ISSUE

[PDF of this issue](#)

:: Foreword: World Antimicrobial Awareness Week 2025 — Act Now: Protect Our Present, Secure Our Future

:: Vital Surveillances: Comparative Analysis of Antibiotic Resistance and Genomic Characteristics of Enterococcus faecium and Enterococcus lactis Along the Food Chain — 5 PLADs, China, 2015–2024

:: Vital Surveillances: Antibiotic Susceptibility of Nocardia Clinical Isolates Collected from Chinese Patients — China, 2014–2024

:: Preplanned Studies: High Prevalence and Genomic Characterization of Extended-Spectrum β -Lactamase-Producing Escherichia coli in the Yellow River and Source Water from A One Health Perspective — Henan Province, China, 2023–2024

:: Preplanned Studies: Genomic Surveillance of Salmonella London and Rissen Reveals International Transmission Patterns and Expanding Antimicrobial Resistance — Shanghai Municipality, China, 2020–2024

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Detection of wild poliovirus in wastewater in Germany: risk and recommendations

13 Nov 2025

Protecting infants against respiratory syncytial virus this winter — ECDC issues advice

13 Nov 2025

Surveillance and monitoring

Communicable disease threats report, 8 - 14 November 2025, week 46

14 Nov 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 November 2025 and includes updates on measles, dengue, mpox, respiratory viruses, West Nile virus, dengue, chikungunya, Ebola and poliovirus detection in wastewater.

Surveillance and monitoring

Seasonal surveillance of dengue in the EU/EEA

14 Nov 2025

This report gives an overview of the countries and areas where dengue cases – and their corresponding case numbers - have been reported to the European surveillance portal for infectious diseases (EpiPulse).

Surveillance and monitoring

Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2025

14 Nov 2025

Update providing weekly overview of the countries and areas where chikungunya virus disease cases have been reported.

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025

Ten new medicines recommended for approval; another four medicines recommended for extension of their therapeutic indications

14 November 2025

.....
.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.

White House, HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders; Memoranda; Proclamations

No new digest content identified.

Department of State

Press Releases - Selected

No new digest content identified.

HHS

Press Room - Selected

Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research

WASHINGTON—NOVEMBER 11, 2025—The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) today announced that Richard Pazdur, M.D., has been appointed director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the founding director of its Oncology Center of Excellence.

NIH [to 15 Nov 2025]

<http://www.nih.gov/>

News Releases

Dr. Kyle Walsh selected to lead the National Institute of Environmental Health Sciences

November 13, 2025 — Dr. Walsh is the institute's seventh director and will also serve as director of the National Toxicology Program.

FDA

Press Announcements - Selected

FDA News Release

November 11, 2025 - Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research

FDA CBER

Latest News

No new digest content identified.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

No future meetings posted.

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments

A Notice by the Food and Drug Administration on 10/02/2025

DATES: The meeting was held on virtually on **November 13, 2025**, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET).

[Briefing Materials for the November 13, 2025 Meeting of the Pediatric Advisory Committee](#)

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified.

ACIP

2026 Meetings Schedule

- February 25-26
- June 24-25
- October 21-22

Notice: Meeting of the Advisory Committee on Immunization Practices

A Notice by the Centers for Disease Control and Prevention on 11/13/2025

DATES: The meeting will be held on December 4, 2025, from 9:00 a.m. to 5:30 p.m., EST and December 5, 2025, from 8 a.m. to 5 p.m., EST..

Matters to be Considered:

The agenda will include discussions on vaccine safety, the childhood and adolescent immunization schedule, and hepatitis B vaccines. The agenda will include updates on ACIP workgroups. **Recommendation votes may be scheduled for hepatitis B vaccines. Vaccines for Children (VFC) votes may be scheduled for hepatitis B vaccines.** Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/acip/index.html>.

Meeting Information:

The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website <https://www.cdc.gov/acip>.

Written Public Comment:

The docket will be opened to receive written comments November 13-24, 2025. Written comments must be received no later than November 24, 2025. [Docket No. CDC-2025-0783]

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP's Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral comment before the meeting according to the procedures below.

Procedure for Oral Public Comment:

All persons interested in making an oral public comment at the December 4-5, 2025 ACIP meeting must submit a request at <https://www.cdc.gov/acip/meetings/index.html> between November 13-24, 2025, and no later than 11:59 p.m. EST, November 24, 2025, according to the instructions provided.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

September 25, 2025 / No. 36

No new edition identified.

National Vaccine Program Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV Meeting – TBD [To be re-scheduled from original date January 29, 2025]

:::::::

NSF

News

No new digest content identified.

:::::::

U.S. Congress

House of Representatives

No new digest content identified.

U.S. Senate

Senate Health, Education, Labor, and Pensions (HELP) Committee

No new digest content identified.

:::::::

Supreme Court, Federal & Appellate Courts

No new digest content identified.

:::::::

:::::::

U.S. States

[15 Governors Launch Governors Public Health Alliance to Safeguard Public Health, Strengthen Preparedness, and Coordinate Across Borders](#)

Nonpartisan initiative will be supported by GovAct and help states and territories to coordinate and address health threats across state lines

WASHINGTON – Today, Governors Bob Ferguson (WA), Josh Green (HI), Maura Healey (MA), Kathy Hochul (NY), Tina Kotek (OR), Ned Lamont (CT), Lou Leon Guerrero (GU), Dan McKee (RI), Matt Meyer (DE), Wes Moore (MD), Phil Murphy (NJ), Gavin Newsom (CA), Jared Polis (CO), JB Pritzker (IL), and Josh Stein (NC) announced the launch of the Governors Public Health Alliance, a new coalition of governors designed to protect the health of people across the U.S.

The Governors Public Health Alliance will serve as a nonpartisan coordinating hub for governors and their public health leaders. The Governors Public Health Alliance will support Governors and their states in coordinating and collaborating **to protect the public's health by facilitating data sharing and communication about health threat detection, emergency preparedness and response, public health guidance and policy, and deployment of experts.**

The Governors Public Health Alliance supports national coordination on public health at the gubernatorial level – **complementing existing mechanisms and interfacing with entities like**

the Northeast Public Health Collaborative and West Coast Health Alliance. The Governors Public Health Alliance will serve as a unified, cross-state liaison with the global health community and will facilitate cross-state collaboration by bringing together regional and other groups to share best practices and surface common challenges, **elevating national considerations for vaccine policy and regulatory solutions to keep science front and center.**

The Alliance welcomes further engagement across Governors' Offices and with public health associations and other relevant groups...

"While Donald Trump and RFK Jr. turn their backs on public health, Governors are stepping up to make sure our residents have the health care they need and deserve," said Massachusetts Governor Maura Healey. "Massachusetts is glad to join this coalition with states from across the country to build on the work we've been doing in the northeast to safeguard public health, including access to vaccines."...

... Supported by GovAct and Public Health Experts

The Governors Public Health Alliance is supported by GovAct, a nonprofit, nonpartisan initiative that supports governors in protecting fundamental freedoms, including public health. The Alliance is guided by a bipartisan set of public health advisors:

- :: Dr. Mandy Cohen, former CDC Director and North Carolina Secretary of Health and Human Services;
- :: Dr. Anne Zink, former Alaska Chief Medical Officer; and
- :: Dr. Raj Panjabi, former White House Senior Director for Global Health Security and Biodefense; as well as
- :: Amb. Nina Hachigian, former U.S. Special Representative for City and State Diplomacy.

As an initiative of GovAct, the Alliance is also guided by GovAct's Bipartisan Advisory Board of former governors — Arne Carlson (R-MN), Jim Doyle (D-WI), Deval Patrick (D-MA), Marc Racicot (R-MT), Kathleen Sebelius (D-KS), and Bill Weld (R-MA) — and former senior federal officials Sally Yates and Larry Thompson.

"With many health threats at our doorstep, collaboration and communication between Governors is essential to protect the health of families and save lives," said Dr. Mandy Cohen, former CDC Director and former North Carolina Secretary for Health and Human Services. "This alliance creates the framework to support the national coordination needed to safeguard communities."...

.....
.....
.....

U.S. Medical Societies, Health Organizations

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 04 Sep 2025)

News

No new digest content identified.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 04 Sep 2025)

ACP News

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 04 Sep 2025)

News releases and statements

Plaintiffs in AAP v. Kennedy File Amended Complaint Seeking Reconstitution of ACIP, Addressing Harms of Shared Clinical Decision Making

Last Updated November 06, 2025

Plaintiffs in American Academy of Pediatrics et al. v. Robert F. Kennedy, Jr. et al. today announced the filing of an amended complaint in the U.S. District Court for the District of Massachusetts, **expanding its plea to request that the Advisory Committee on Immunization Practices (ACIP) be disbanded and reconstituted under court supervision.**

The amended complaint asserts that the current ACIP has been arbitrarily and capriciously -- and therefore unlawfully -- appointed, necessitating that all decisions made by the committee be declared null and void. This action underscores the plaintiffs' commitment to restoring lawful, science-based vaccine policy and safeguarding public health.

The amended complaint also brings to light the significant harms caused by the Secretary's directive and subsequent decision-making by ACIP to change the CDC's immunization schedule for Covid-19 vaccines to shared clinical decision making (SCDM). The SCDM designation, without being accompanied by additional guidance from CDC for families and clinicians as it typically is for other vaccines, has placed additional burdens on clinicians and families. In practice, this has caused confusion among doctors, pharmacists, and patients, leading to denial of vaccines, increased stress, and uncertainty about eligibility and insurance coverage.

"This case is about safeguarding public health and ensuring that vaccine policy reflects science and transparency. **Our goal is to restore confidence in the systems that guide our nation's immunization policies,**" said Richard Hughes IV, partner at Epstein Becker Green and lead counsel for the plaintiffs. "With this litigation, we are reinforcing the principle that public health decisions must be lawful, transparent, and rooted in science."

"The US government must not be allowed to restrict the ability of Americans to protect themselves and their families. We are bringing this lawsuit to ensure continued access to life-saving vaccines. The Secretary's actions have made it significantly harder for people to get vaccinated, sown unfounded doubt in vaccines, and contributed to mistrust of medical science knowledge for infectious diseases including Covid-19, measles, and hepatitis B. This is leaving individuals, health care systems, and communities increasingly vulnerable to severe disease and destabilizing outbreaks. Our nation's infectious diseases physicians will not allow this dangerous injustice to stand," said IDSA President Ronald Nahass, MD, MHCM, FIDSA.

The original complaint challenged actions undermining evidence-based immunization policy. The amended filing strengthens plaintiffs' arguments by adding new prayers for relief and detailed evidence of harm caused by Secretary Kennedy's broad assault on the United States' vaccine infrastructure.

The American Academy of Pediatrics

The American Public Health

The American College of Physicians

The Infectious Diseases Society of.

The Massachusetts Public Health Alliance

The Society for Maternal-Fetal Medicine

IDSA releases RSV and flu vaccine guidelines for people who are immunocompromised

Last Updated November 04, 2025

The Infectious Diseases Society of America released new flu and RSV vaccination guidelines for adults and children who are immunocompromised. Experts in infectious diseases recommend that all adults and children who are immunocompromised receive an age-appropriate flu vaccine for the 2025-2026 season. All adults and adolescents who are immunocompromised should receive the RSV vaccine, and for children under the age of 18, parents and/or guardians should consult their children's health care providers.

The panel noted that live-attenuated flu vaccines, such as FluMist, are not recommended for people who are immunocompromised or the people living in their household. Patients should discuss vaccination timing and other individual considerations with their health care providers...

The recommendations are based on a systematic literature review conducted by the Vaccine Integrity Project and supplementary searches and evidence reviews conducted by a panel of experts in infectious diseases. The panel included scientists with expertise in adult and pediatric infectious diseases, including treating patients who are immunocompromised; vaccines and vaccine research; and transplant medicine.

In addition to Dr. Baden, guideline authors include Anoma Nellore, MD; Paul Goepfert, MD; Chen (Sabrina) Tan, MD, FIDSA; Kristina Bajema, MD, MSc; Katherine Belden, MD, FIDSA; Dean Blumberg, MD; Morgan Katz, MD, MHS; Daniel Kaul, MD, FIDSA; Tanvi Sharma, MD, MPH; Shweta Anjan, MD, FIDSA; Ella Ariza-Heredia, MD, FIDSA; Francisco Magana, MD; Timothy Minniear, MD, MSc; Jennifer Loveless, MPH; Dipleen Kaur, MPH; Elizabeth York, MPH; and Yngve Falck-Ytter, MD, AGAF.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>

(Accessed 04 Sep 2025)

News Releases

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 04 Sep 2025)

News

No new digest content identified.

Massachusetts Public Health Alliance (MPHA)

<https://mapublichealth.org/press-room/>

(Accessed 04 Sep 2025)

Press Room

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 04 Sep 2025)

Press Center - Latest News

No new digest content identified.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 04 Sep 2025)

Statements, Releases

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>
(Accessed 04 Sep 2025)
Recent Press Releases
No new digest content identified.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>
(Accessed 04 Sep 2025)
Latest News
No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>
(Accessed 04 Sep 2025)
Latest News
No new digest content identified.

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>
(Accessed 04 Sep 2025)
News and Updates
No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions

.....

Kaiser Family Foundation/KFF [15 Nov 2025]
https://www.kff.org/search/?post_type=press-release
Newsroom

[Tracking Key HHS Public Health Policy Actions Under the Trump Administration](#)

Authors: [Josh Michaud](#) and [Jennifer Kates](#)
Published: Nov 12, 2025

Since assuming office for a second term, President Trump and officials in his administration have instituted numerous policy actions through the Department of Health and Human Services (HHS) affecting public health in the U.S. This resource lists and briefly describes key actions in the order in which they were first issued, reported or announced, with subsequent linked actions and related outcomes also included with each entry. As new policy changes occur, they will be added.

This resource is not meant to be exhaustive of all administration actions related to public health, as many other federal policy changes – including outside of HHS – have public health implications but are not captured here.

.....

Vaccine Integrity Project – CIDRAP

<https://www.cidrap.umn.edu/vaccine-integrity-project>
No new digest content identified.

.....

Paul Offit, MD – Beyond the Noise

Substack: <https://pauloffit.substack.com/>

No new digest content identified.

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [15 Nov 2025]

<https://alleninstitute.org/news-press/>

News

Featured

[Scientists unveil the world's most comprehensive AI-powered tool for neuroscience: Brain Knowledge Platform](#)

Nov 13, 2025

Massive, first-of-its-kind data resource aims to accelerate medical breakthroughs in brain diseases like Alzheimer's and Parkinson's

BMGF - Gates Foundation [15 Nov 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

CARB-X [15 Nov 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [15 Nov 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [15 Nov 2025]

<http://cepi.net/>

CEPI News, Blog

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 15 Nov 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [15 Nov 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [15 Nov 2025]

<https://dndi.org/press/press-releases/>

Press Releases

10 Nov 2025

[**COP 30: The climate crisis is also a crisis for neglected diseases, warns DNDI**](#)

Duke Global Health Innovation Center [15 Nov 2025]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [15 Nov 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

13 November 2025

[**KALUMA trial confirms safety and efficacy of next-generation malaria therapy**](#)

Emory Vaccine Center [15 Nov 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [15 Nov 2025]

<http://www.euvaccine.eu/>

News

No new digest content identified.

Fondation Merieux [15 Nov 2025]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [15 Nov 2025]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 15 Nov 2025]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GE2P2 Global Foundation [15 Nov 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

Digests

:: [Vaccines and Global Health: The Week in Review](#) - *Current edition*

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

GHIT Fund [15 Nov 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 15 Nov 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

11 November 2025

[Global Fund Welcomes UK's Leadership and Pledge for the Eighth Replenishment](#)

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed the United Kingdom's pledge of GBP850 million to the Global Fund's Eighth Replenishment, reaffirming the UK's long-standing commitment to global health and the f...

10 November 2025

[Francophone Africa and the Global Fund Join Forces to Strengthen Public Financial Management and Promote Health Sovereignty](#)

The government of Senegal and the Global Fund today concluded a high-level regional meeting that marks a turning point in aligning health financing with national public financial management (PFM) systems. Over four days, representatives of finance an...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [15 Nov 2025]

<https://www.glopid-r.org/>

News & Events

No new digest content identified.

Hilleman Laboratories [15 Nov 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [15 Nov 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [15 Nov 2025]

<https://www.humanimmunomeproject.org/>

News

[Leading Immunologists Convene at Cold Spring Harbor to Decode the Human Immune System](#)

Historic Banbury Conference Launches AI-powered Initiative to Decipher Human Immunity COLD SPRING HARBOR, NY – November 14, 2025 – The Human Immunome Project (HIP) convened the first meeting of their Scientific Partner Network, featuring the world’s leading systems immunology experts, at Cold Spring Harbor Laboratory’s prestigious Banbury Center, where the Human Genome Project strategy was incubated....

2025-11-13

IAVI [15 Nov 2025]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [15 Nov 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 15 Nov 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01 2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on “Adaptive Clinical Trials” on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States)

Regulatory Chair: Dr. Christian Roes (EC, Europe)

Date of Step 2b: 25 June 2025 Status: Step 3

Ongoing Public Consultations		^
>	M4Q(R2) EWG Revision of M4Q(R1)	
>	Q3E EWG Guideline for Extractables and Leachables	
>	E20 EWG Adaptive Designs for Clinical Trials	

<https://www.ich.org/page/public-consultations>

ICRC [to 15 Nov 2025]

<https://www.icrc.org/en/news>

News

No new digest content identified.

IFFIm [15 Nov 2025]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 15 Nov 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

Press release 15/11/2025

Alliance for the Amazon: IFRC and TNC present a 10-year commitment to strengthen community resilience and climate adaptation

Press release 14/11/2025

Beyond the blackouts: Ukraine facing its hardest winter yet, IFRC warns

Press release 10/11/2025

From earthquake to typhoons: Philippines struggles against relentless catastrophes

IPPS - International Pandemic Preparedness Secretariat [15 Nov 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [15 Nov 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 15 Nov 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

blog

12 November 2025 - 7 min read

Bulwarks of science diplomacy under attack? The role of international research infrastructures in current geopolitics

From CERN to ITER, international research infrastructures have long symbolized what global cooperation in science can achieve, even in times of deep political tension. In this guest op-ed, Jan Marco Müller examines how these “lighthouses of science diplomacy” are now navigating growing geopolitical pressures, and what they can do to preserve collaboration and trust across borders.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

No new digest content identified.

IVAC [15 Nov 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [15 Nov 2025]

<http://www.ivl.int/>

IVI News & Announcements

International Vaccine Institute Board of Trustees convenes in Rwanda, underscoring deepening commitment to Africa's vaccine ecosystem and global health collaboration

13 November 2025, KIGALI, Rwanda — The Board of Trustees of the International Vaccine Institute (IVI) convened in Kigali, Rwanda, this week for its meeting and a series of engagements with national

and regional partners. The gathering underscored IVI's commitment to strengthening vaccine research, development, and delivery across Africa in partnership with governments, academic institutions, and public health leaders to advance global health and pandemic preparedness...

Johns Hopkins Center for Health Security [15 Nov 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 15 Nov 2025]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 15 Nov 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Conflict in Sudan

[People face extreme malnutrition in Sudan's protracted crisis](#)

Press Release 11 Nov 2025

National Academy of Medicine - USA [to 15 Nov 2025]

<https://nam.edu/programs/>

News, Stories, Insights

Nov 12, 2025 *News*

[Academies of Medicine Launch Global Coalition to Advance Climate–Health Action; Supports Brazil's Belém Health Action Plan at COP30](#)

Nov 11, 2025 *News*

[High Level Independent Panel Calls for Urgent Action from G20 and Other Nations to Close the Global Pandemic Financing Gap](#)

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 15 Nov 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

PATH [15 Nov 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

[EuTYPH-C Inj.® Multi-dose demonstrates strong safety and immunogenicity: Results now available from a Phase 3 study](#)

November 12, 2025 by PATH

Seattle, United States & Seoul, Republic of Korea— PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® Multi-dose is manufactured by EuBiologics Co., LTD, Republic of Korea.

The results, published in The Lancet Global Health, demonstrate that EuTYPH-C Inj.® Multi-dose is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa...

Sabin Vaccine Institute [15 Nov 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [15 Nov 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Feature Story

[UNAIDS releases updated guidelines for conducting National AIDS Spending Assessments](#)

14 November 2025

UNAIDS is releasing an updated version of its guidelines for conducting National AIDS Spending Assessments (NASA). The guidelines are aimed at NASA implementers and HIV programme managers utilizing HIV expenditure data to influence budgetary, policy and programmatic decisions. NASA is a comprehensive, systematic approach to tracking HIV expenditures and analyzing financial resources dedicated to the HIV response within a country. NASA results can identify which programmes and interventions are most underfunded and require prioritization, as well as those dependent on external sources and thus most vulnerable to external shocks. By providing this granular view, NASA data supports sustainability planning and integration into broader health financing systems, while also identifying potential inefficiencies and cost-saving opportunities, increasing evidence for allocative efficiency measures and fostering a performance-based financing culture aligned with value-for-money principles.

UNICEF [to 15 Nov 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 13 November 2025

[Over 1.7 million children live in areas affected by strongest typhoon to hit the Philippines this year](#)

MANILA, 13 November 2025, – More than 1.7 million children are impacted by Super Typhoon Fung-wong, which made landfall in the Philippines on 9 th November. The severe storm has wreaked havoc to children's homes, schools, and access to health services across 16 regions in the archipelago that is already exhaust...

Unitaid [15 Nov 2025]

<https://unitaid.org/>

Press Releases

News releases

[Unitaid partners with Japan's SORA Technology and WHO to pilot AI-driven malaria prevention in Mozambique](#)

14 November 2025

Vaccine Equity Cooperative [nee Initiative] [15 Nov 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [15 Nov 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [15 Nov 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter October 2025

Vaccine Update is our monthly email newsletter that will keep you up to date on current vaccine-related issues. For quick access to 2025 *Vaccine Update* “Fast Facts” articles, scroll to the bottom of this page.

Wellcome Trust [15 Nov 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 15 Nov 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

29th Annual Jonathan Lax Memorial Lecture at Wistar Honors Richard Jefferys, Changemaker Activist Who Expanded Access to New Drugs, Clinical Trials, and HIV Research Funding

PHILADELPHIA — (Nov. 11, 2025) — On Monday, Nov. 17th at 6:30 pm EST, Richard Jefferys, Basic Science, Vaccines and Cure Project director at the Treatment Action Group (TAG), delivers the 29th annual Jonathan Lax Memorial Lecture at The Wistar Institute in recognition of his outstanding contributions to HIV research, education and advocacy. Jefferys’ talk, “Community Advocacy and HIV Cure-Directed Research,” is open to the public virtually through an online live stream...

World Bank [to 15 Nov 2025]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [15 Nov 2025]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [15 Nov 2025]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [15 Nov 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [15 Nov 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [15 Nov 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [15 Nov 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [15 Nov 2025]

<https://ifpma.org/>

News & Resources

Statement 12 Nov 2025

Biopharmaceutical CEOs Roundtable met in Berlin

12 NOVEMBER 2025, Berlin – The Biopharmaceutical CEOs Roundtable (BCR), a global policy platform representing the world's leading biopharmaceutical companies, convened last week in Berlin to discuss how pharmaceutical innovation can drive better health outcomes, strengthen economies, and enhance global health security. The BCR delegation also met with Federal Chancellor Merz, along with key members...

International Alliance of Patients' Organizations – IAPO [15 Nov 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

AMATA Calls for all AU Member States to back the African Medicines Agency

Tuesday, 28 October 2025

AMATA [African Medicines Agency Treaty Alliance] Calls for all AU Member States to back the African Medicines Agency and for regulatory system strengthening to be recognised as a key element for a safer, healthier and prosperous Africa

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [15 Nov 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

CSL Sequirus

News Releases - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases

[Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent](#)

November 14, 2025 6:45 am EST

:: CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications

:: Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline

Nanogen

News - No new digest announcements identified.

Novartis

News

[Novartis Phase III trial for next-generation malaria treatment KLU156 \(GanLum\) meets primary endpoint, with potential to combat antimalarial resistance](#)

Nov 12, 2025

- Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine)
- Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating to 99.2% under conventional per protocol analysis

- If approved, GanLum would represent first major innovation in malaria treatment since 1999, with potential to kill drug-resistant parasites and block transmission
- Novel ingredient in GanLum, ganaplacide, has entirely new mechanism of action, discovered after screening 2.3 million molecules
- Highlights Novartis long-term commitment to combating malaria, with more than 1.1 billion treatment courses of Coartem provided largely at no profit, and multiple novel antimalarial compounds in development

Novavax

[Press Releases](#) - No new digest announcements identified.

Pfizer

[Recent Press Releases](#) - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Serum Institute

[News & Announcements](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified.

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

[:: Journal Watch](#)
[:: Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 11: E769-822 November 2025

<https://journalofethics.ama-assn.org/issue/electronic-health-record-evolution>

Electronic Health Record Evolution

Patients' charts once hung at the feet of their hospital beds, and their purpose was to serve as the record of care for a particular patient. Now, electronic health records (EHRs) have several functions and serve many stakeholders' interests. This theme issue investigates which kinds of work EHRs should do—and for whom—and whose interests EHRs should serve when information is entered, organized, reviewed, responded to, extracted, or amended. This issue also investigates which values should inform EHR stewardship and innovation decisions and from whose perspectives the stakes of those decisions should be framed.

American Journal of Human Genetics

Nov 06, 2025 Volume 112 Issue 11 p2563-2814

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

Rare diseases affect more than 5% of the population in the United States. Classically, rare diseases are diagnosed through a phenotype-first approach in which individuals with distinct clinical features undergo genetic testing to identify the underlying genetic basis of their disorder. This approach can lead to ascertainment bias toward individuals with more severe or well-characterized phenotypes, leaving many affected individuals without a diagnosis. A genotype-first approach could increase diagnoses and provide insight into the phenotypic spectrum and prevalence of rare diseases, but this approach is difficult to apply at scale.

[Reviewed earlier]

American Journal of Infection Control

November 2025 Volume 53 Issue 11 p1131-1242
<http://www.ajicjournal.org/current>
[Reviewed earlier]

American Journal of Preventive Medicine

November 2025 Volume 69 Issue 5
<https://www.ajpmonline.org/current>
Reviewed earlier]

American Journal of Public Health

November 2025 115(11)
<http://ajph.aphapublications.org/toc/ajph/current>
Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 4 (Oct 2025)
<https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-4.xml>
Reviewed earlier]

Annals of Internal Medicine

October 2025 Volume 178, Issue 10
<https://www.acpjournals.org/toc/aim/current>
[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 347 October 2025
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/346/suppl/C>
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>
(Accessed 15 Nov 2025)
[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>
(Accessed 15 Nov 2025)
[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>
(Accessed 15 Nov 2025)

[Antimicrobial stewardship programs in primary and secondary care settings in India: current challenges, facilitators, perceptions, and impact – a scoping review](#)

Antimicrobial stewardship programs (AMSP) is a major initiative of World Health Organization Global Action Plan (WHO-GAP) to address antimicrobial resistance (AMR). The program aims to promote the rational use...

Authors: Rajalakshmi Rajendran, Shravya Chitrapady, MU Tejashree, Kapu Haritha, Jayaraj Mymbilly Balakrishnan, Sreedharan Nair, Mohammed Salim Karattuthodi, Sohil Khan, Sneh Shalini, Rangaswamy Uday Kumar, Nettoor Veettil Vajid and Girish Thunga

Citation: BMC Infectious Diseases 2025 25:1539

Content type: Systematic Review Published on: 11 November 2025

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 15 Nov 2025)

Research on issues in the protection of clinical trial human subjects in China: a Delphi study

This study aims to identify current deficiencies in the protection of human subjects participating in clinical trials in China and propose strategies for safeguarding their rights.

Authors: Xiuqiao Yang, Hong Lin, Shuning Liu, Chunyan Ai, Zhanghong Cai, Rong Yu, Xiaoyi Xu, Jinghong Gao, Yuwen Chen and Ping Wen

Citation: BMC Medical Ethics 2025 26:161

Content type: Research Published on: 14 November 2025

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 15 Nov 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 15 Nov 2025)

No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 15 Nov 2025)

The prolonged impact of the COVID-19 pandemic on routine childhood vaccinations in Armenia: a time-series analysis

The COVID-19 pandemic caused disruptions to health services, including routine vaccination programs, affecting the uptake and timeliness of childhood vaccinations. This study explored the continued impact of t...

Authors: Anya Agopian, Tamara Sedrakyan, Diana Muradyan and Gayane Sahakyan

Citation: BMC Public Health 2025 25:3948

Content type: Research Published on: 14 November 2025

Determinants of uptake of childhood immunization in Gboko, Benue State, Nigeria

Immunization is among the most impactful, effective, and cost-effective public health interventions for preventing deaths and illnesses associated with several childhood infectious diseases worldwide. Given th...

Authors: Bemhembamba Iba, Vershima Daniel Zar and Joseph Oteng

Citation: *BMC Public Health* 2025 25:3940
Content type: Research Published on: 14 November 2025

Cost-effectiveness analysis of different types of human papillomavirus vaccination to prevent cervical cancer in Iran

Cervical cancer (CC) remains a major public health concern, especially in low- and middle-income countries (LMICs), where prevention and screening access are limited. Iran has a relatively low incidence of CC ...

Authors: Negin Bashari, Majid Davari, Ali Akbarisari, Elahe Khorasani and Rajabali Daroudi

Citation: *BMC Public Health* 2025 25:3927

Content type: Research Published on: 13 November 2025

Hepatitis B vaccination coverage and associated factors among adults in Somalia: a cross-sectional study

Hepatitis B virus (HBV) remains a significant global health concern with substantial morbidity and mortality. Although effective vaccines exist, vaccination coverage remains suboptimal in many low- and middle-...

Authors: Sakariye Abdullahi Hassan –Tuuryare, Kiprotich Kimutai Timothy and Muktar Hassan Mohamud

Citation: *BMC Public Health* 2025 25:3917

Content type: Research Published on: 12 November 2025

Accessibility of Ontario pharmacies offering COVID-19 vaccination by rurality, community material deprivation, and ethnic concentration: a repeated cross-sectional geospatial analysis

Community pharmacies are largely recognized as geographically accessible; yet concerns arise regarding inequitable access to COVID-19 vaccination, especially during early vaccine availability.

Authors: Mhd Wasem Alsabbagh, Markus Wieland, Shayna Pan, Nancy M. Waite, Sherilyn K.D. Houle and Kelly Grindrod

Citation: *BMC Public Health* 2025 25:3915

Content type: Research Published on: 12 November 2025

Unequal access in a universal health system: COVID-19 vaccination and health services utilization among international migrants in Brazil

The COVID-19 pandemic has intensified existing health inequities, particularly among international migrants, who often face barriers to healthcare access and vaccination. In Brazil, where the Unified Health Sy...

Authors: Juliana Soares Tenório De Araújo, Letícia Perticarrara Ferezin, Heriederson Sávio Dias Moura, Rander Junior Rosa, Ariela Fehr Tártaro, Ione Carvalho Pinto, Mônica Chiodi Toscano de Campos and Ricardo Alexandre Arcêncio

Citation: *BMC Public Health* 2025 25:3905

Content type: Research Published on: 11 November 2025

Public awareness and acceptance of malaria vaccine in Sub-Saharan Africa: a systematic review

The African continent continues to experience a high prevalence of malaria more than three years after the licensure of the first malaria vaccine. This study aimed to review relevant literature on malaria vacc...

Authors: Efosa Ekhatior, Victor Godwin Essien, Oluwatosin Esther Afolabi, Moses Ikpomwonsa Okundaye and Temitope Adewonbi

Citation: *BMC Public Health* 2025 25:3890

Content type: Systematic Review Published on: 11 November 2025

Barriers to COVID-19 vaccination and strategies to increase trust and uptake among racial and ethnic minorities with HIV in South Florida: a qualitative study

People with HIV (PWH) from racial and ethnic minority groups in the United States (US) face a high risk for severe COVID-19 outcomes and have low uptake of the COVID-19 vaccine primary series and booster doses...

Authors: Daisy Ramírez-Ortiz, Tatyana Moise, Seyedeh Yasaman Alemohammad, Mariolga Aymat, Aaliyah Gray, Michele Jean-Gilles, Diana M. Sheehan, Robert Ladner and Mary Jo Trepka

Citation: *BMC Public Health* 2025 25:3885

Content type: Research Published on: 10 November 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 15 Nov 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2025 - Volume 30 - 5

<https://ebm.bmj.com/content/30/5>

[Reviewed earlier]

BMJ Global Health

October 2025 - Volume 10 - 10

<https://gh.bmj.com/content/10/10>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - September 2025

<https://thebulletin.org/magazine/2025-09/#post-heading>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 11, November 2025, 641-752

<https://www.who.int/publications/journals/bulletin/>

Theme issue: traditional medicine and global health

Integrating traditional medicines into health systems.

[No authors listed]

Bull World Health Organ. 2025 Nov 1;103(11):645-646. doi: 10.2471/BLT.25.021125.

PMCID: PMC12579966

Indigenous rights, health and traditional medicine systems.

Redvers N, Menzel K, Carroll D, Zavaleta C, Kokunda S, Kobei DM, Rojas JN.

Bull World Health Organ. 2025 Sep 22;103(11):722-729. doi: 10.2471/BLT.24.292882.

PMCID: PMC12578532

Regulatory frameworks and evidence requirements for traditional, complementary and integrative medicines.

Chen Q, Cheng HJ, Bian ZX, Lyu AP, Yang Y, Chan KW.

Bull World Health Organ. 2025 Sep 3;103(11):696-707C. doi: 10.2471/BLT.25.293437.

PMCID: PMC12578520

Integration of traditional and complementary medicine into primary health care systems: a systematic review.

Wang M, Liu Z, Sun Y, Zhang Y, Ghaffar A, Ren M.

Bull World Health Organ. 2025 Sep 3;103(11):675-684C. doi: 10.2471/BLT.25.293465.

PMCID: PMC12578535

Cell

Oct 30, 2025 Volume 188 Issue 22 p6105-6390

<https://www.cell.com/cell/current>

[Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 6 November 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 5 Pages: 969-1224 November 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

Clinical Therapeutics

November 2025 Volume 47 Issue 11 p957-1088

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 22 Issue 5, October 2025

<https://journals.sagepub.com/toc/ctja/22/5>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 15 Nov 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 158 November 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/158/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 5 / October 2025

<https://www.liebertpub.com/toc/crispr/8/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2025 - Volume 38 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

PAEDIATRIC AND NEONATAL INFECTIONS

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 15 Nov 2025]

[No new digest content identified]

Cytotherapy

November 2025 Volume 27 Issue 1271 p121-1362

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 3 Pages: 165-252 September 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 121 November 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/121/suppl/C>

Research article Open access

[**Respiratory syncytial virus \(RSV\) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness \(CoVE\) observational study**](#)

Elie-Tino Godonou, Amy P. Callear, Casey L. Juntilla-Raymond, Dolapo Raji, ... Emily T. Martin
Article 105961

Research article Open access

[**Global childhood diarrhoea prevalence and its determinants: a systematic meta-analytic assessment, 1985–2024**](#)

Zahir M. Tag, Hadeel Alashwal, Hiam Chemaitelly, Laith J. Abu-Raddad
Article 105956

EMBO Reports

Volume 26 Issue 21 6 November 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 10—October 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 52 September 2025

<https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 5 Pages: 1-43 September–October 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 2 - Summer 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

Roundtable: Global Governance in Hard Times

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 5, October 2025

<https://academic.oup.com/eurpub/issue/35/5>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

November/December 2025 Volume 104, Number 6

<https://www.foreignaffairs.com/issues/2025/104/5>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 15 Nov 2025]

[No new digest content identified]

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 15 Nov 2025]

Review

Published on 11 Nov 2025

[A long journey towards genome editing technologies in plants: a technical and critical review of genome editing technologies](#)

Dylan Gallo, Anne-Cécile Meunier, Christophe Périn

Frontiers in Genome Editing

doi 10.3389/fgeed.2025.1663352

Editorial

Accepted on 10 Nov 2025

[Editorial: Social aspects of crop genome editing](#)

Srividhya Venkataraman, Kathleen Hefferon

Frontiers in Genome Editing

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 15 Nov 2025]

Editorial

Published on 12 Nov 2025

[Editorial: Future directions and current trends in cellular therapies](#)

Ruxandra Irimia, Eleni Gavriilaki

Frontiers in Medicine

doi 10.3389/fmed.2025.1732925

Gene Therapy – Nature

Volume 32 Issue 5, October 2025

<https://www.nature.com/gt/volumes/32/issues/5>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 15 Nov 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 15 Nov 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 15 Nov 2025]

[Constructing and contesting industry's role in multistakeholder governance: a qualitative analysis of responses to WHO consultations](#)

Authors: Amber van den Akker, Xinmei Sun, Britta K. Matthes, Kathrin Lauber and Anna B. Gilmore

Content type: Research 11 November 2025

Multistakeholderism as a norm stating that global public issues should be addressed by all those who affect or are affected by this issue, has become increasingly institutionalised in global governance, including the United Nations (UN) system. Despite an increasing body of evidence showing the risks of corporate capture of multistakeholder governance (MSG) and its related inability to deliver effective public health outcomes, this approach is increasingly common. While research shows that industry actors have pushed for MSG, and others have questioned its legitimacy, how MSG is constructed, legitimised and contested by different actors has not been systematically studied. Analysing responses to World Health Organization (WHO) consultations related to non-communicable diseases (NCDs) and associated risk factors, this study examines how actors construct or contest the legitimacy of MSG to address these public health issues.

Health and Human Rights

Volume 27, Issue 1, June 2025

<https://www.hhrjournal.org/volume-27-issue-1-june-2025/>

SPECIAL SECTION - FIGHT FOR RIGHTS VIEWPOINT SERIES

[Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 4 - October 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 10, November 2025

<https://academic.oup.com/heapol/issue/40/10>

[New issue; No digest content identified]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 15 Nov 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 19-20 / October 2025

<https://www.liebertpub.com/toc/hum/36/19-20>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 15 Nov 2025]

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Nov 11, 2025 Volume 58 Issue 11 p2609-2916

<https://www.cell.com/immunity/current>

Reviews

[**Human immune aging**](#)

Marina Terekhova, Pavla Bohacova, Maxim N. Artyomov

Open Access

Artyomov and colleagues provide an overview of studies on age-related changes in the human immune system, from early flow cytometry research to more recent findings using single-cell and advanced cytometry methods. They explore possible sources of discrepancies in human immune aging research and highlight major challenges that need to be addressed.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 15 Nov 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content/>

[Accessed 15 Nov 2025]

[No new digest content identified]

International Health

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

Review Articles

Editor's Choice

[Cholera burden in Ghana: a systematic review and meta-analysis of prevalence, antimicrobial resistance and risk factors](#)

Frederick Kungu and others

International Health, Volume 17, Issue 6, November 2025, Pages 869–880,

<https://doi.org/10.1093/inthealth/ihaf069>

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 9 (2025): September 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/128>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025

<https://academic.oup.com/ije/issue/54/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 4 22 October 2025

<https://www.emerald.com/ijhrh/issue/18/4>

Table of contents

[Reviewed earlier]

JAMA

November 11, 2025, Vol 334, No. 18, Pages 1605-1688

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies

James D. Chambers, PhD; Julia A. Rucker, MSW, MPH; Daniel E. Enright, MS; et al.

JAMA. 2025;334(18):1672-1675. doi:10.1001/jama.2025.15148

This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.

Special Communication

AI in Medicine

AI, Health, and Health Care Today and Tomorrow-The JAMA Summit Report on Artificial Intelligence

Derek C. Angus, MD, MPH; Rohan Khera, MD, MS; Tracy Lieu, MD, MPH; et al.

free access has active quiz has audio

JAMA. 2025;334(18):1650-1664. doi:10.1001/jama.2025.18490

This Special Communication discusses how health and health care artificial intelligence (AI) should be developed, evaluated, regulated, disseminated, and monitored.

- [Podcast](#): AI, Health, and Health Care

Editorial

Introducing the JAMA Summit

Kirsten Bibbins-Domingo, PhD, MD, MAS; Derek C. Angus, MD, MPH; Hannah Park; Roger J. Lewis, MD, PhD; Rohan Khera, MD, MS; Jennifer Zeis; Annette Flanagan, RN, MA; Gregory Curfman, MD

JAMA

Editor's Note

Artificial Intelligence Across the JAMA Network-A Call for Submissions

T. Y. Alvin Liu, MD; Yulin Hswen, ScD; Robert O. Bonow, MD, MS; Aaron E. Carroll, MD, MS; Cary

P. Gross, MD; Elan L. Guterma, MD, MAS; Rohan Khera, MD, MS; Melina R. Kibbe, MD;

Dost Öngür, MD, PhD; Romain Pirracchio, MD, MPH, PhD; Veronica Rotemberg, MD, PhD;

Matthew Shew, MD, MSCI; Yu Shyr, PhD; Elizabeth A. Stuart, PhD; Kirsten Bibbins-Domingo, PhD, MD,

MAS; Roy H. Perlis, MD, MSc

JAMA

Viewpoint

The Cell and Gene Therapy Access Model

Melissa Majerol, MPH; Aurelia Chaudhury, JD; Cathy Traugott, JD; et al.

JAMA. 2025;334(18):1615-1616. doi:10.1001/jama.2025.16537

This Viewpoint discusses lessons learned from the first negotiation cycle of the Centers for Medicare & Medicaid Services' Cell and Gene Therapy Access Model.

JAMA Insights

Measles

Emily K. Stoneman, MD

has active quiz

JAMA. 2025;334(18):1665-1666. doi:10.1001/jama.2025.14210

This JAMA Insights discusses transmission, clinical presentation, and diagnosis of measles and emphasizes the importance of vaccination to protect those at highest risk for complications from measles, including young children and pregnant individuals.

JAMA Health Forum

November 2025, Vol 6, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

November 2025, Vol 179, No. 11, Pages 1139-1248

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB I Evidence Synthesis

October 2025 - Volume 23 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

November 2025 Volume 77 Issue 5 p797-1008

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 3 September 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-3>

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 6 December 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-6>

Articles

[**Exploring College Men's Human Papillomavirus \(HPV\) Vaccine Behavior and Intention in the United States**](#)

Olivia H. Marshall, Dayna S. Henry, James M. Bishop

Original Paper Open access 14 June 2025 Pages: 1037 - 1048

[**Factors Influencing Influenza Vaccination: A Survey-Based Cross-Sectional Study in the City of Syracuse, Italy**](#)

Fabio Contarino, Claudio Fiorilla, Giancarlo Icardi
Original Paper 26 June 2025 Pages: 1067 - 1078

Boosting Hepatitis B Vaccination Rates Among Healthcare Workers in the State of Minnesota

Brittany Strelow, Elise G. Roxas, Danielle O'Laughlin
Original Paper 11 July 2025 Pages: 1144 - 1149

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

October 2025 - Volume 79 - 10

<https://jech.bmj.com/content/79/10>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 3 September 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 3, August 2025

<https://muse.jhu.edu/issue/55342>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 5 October 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 3 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 7 Pages: 1-1567 October 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 53 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

Public Health, Markets, and Law

[Reviewed earlier]

Journal of Medical Ethics

October 2025 - Volume 51 - 10

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 284 September 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

November/December 2025 - Volume 31 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Public Health Policy

Volume 46, Issue 4 December 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-4>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

November 2025 Volume 22 Issue 232

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 6, August 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 99 • Number 10 • October 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Nov 15, 2025 Volume 406 Number 10517 p2295-2392

<https://www.thelancet.com/journals/lancet/issue/current>

Lecture

[**Advancing women, maternal, newborn, and child health equity**](#)

Quarraisha Abdool Karim, Jivanka Mohan, Zulfiqar A Bhutta

The Lancet Child & Adolescent Health

Dec 2025 Volume 9 Number 12 p817-890, e24-e27

<https://www.thelancet.com/journals/lanchi/issue/current>

[New issue; No digest content identified]

Lancet Digital Health

Sep 2025 Volume 7 Number 9

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Dec 2025 Volume 13 Number 12 e1991-e2179

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

[Scaling HPV vaccination in Africa to eliminate cervical cancer by 2030](#)

Addija Amani, et al.

Articles

[Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis](#)

Élodie Bénard, et al.

Review

[The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation](#)

Farina L Shaaban, et al.

Viewpoint

[Facing up to reality: over-the-counter access to antibiotics in low-income and middle-income countries needs a paradigm shift in thinking](#)

Marc Mendelson, et al.

Lancet Infectious Diseases

Nov 2025 Volume 25 Number 11 p1159-1264, e621-e675

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Oct 2025 Volume 10 Number 10 e804-e88

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2025 Volume 13 Number 10 p857-950, e53-e55

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 8, November 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 103, Issue 3 Pages: 639-939 September 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Nov 05, 2025 Volume 33 Issue 11 p5283-5908
<https://www.cell.com/molecular-therapy/current>
Editorial

Breakthroughs in targeted in vivo gene editing: Overcoming barriers to effective delivery

Paula Cannon, Kiran Musunuru

In vivo gene-editing technologies hold great promise to transform the treatment of genetic conditions, offering new options for conditions long thought to be untreatable. However, despite rapid advancements, one fundamental hurdle remains: how to safely and efficiently deliver editors into the right cells, at the right time, and at the right dose.

Commentaries

Conquering the gene and cell therapy viability crisis: A path paved by ASGCT

Rayne H. Rouse

A storm is brewing within the field of gene and cell therapy (GCT). Despite the rise of safe and efficacious GCT for rare and ultra-rare diseases, the field hovers on the brink of a crisis—one both predictable and preventable. The road to the commercialization of promising GCTs is fraught with regulatory and financial barriers.^{1,2,3,4} Like the frequently referenced “valley of GCT death,” overcoming the “crisis of dropped GCT trials” requires organized, intentional, multi-stakeholder attention, given its broad effects on GCT researchers, biotechnology companies, and, most importantly, patients.

Nature

Volume 647 Issue 8089, 13 November 2025
<https://www.nature.com/nature/volumes/646/issues/8089>
Editorial 11 Nov 2025

Failure is not an option for Africa’s newly launched medicines agency

The inequitable distribution of vaccines during the COVID-19 pandemic was the final proof of the need for more home-grown manufacturing and regulatory capacity across Africa.

Comment 10 Nov 2025

Africa finally has its own drug-regulation agency — and it could transform the continent’s health

If it gets things right, the first major regulator of medicines to launch for 30 years could empower Africa to tackle African challenges around health and disease.

Mwila Mulubwa, Leon Mutesa, Kelly Chibale

Perspective 12 Nov 2025

GREGoR: accelerating genomics for rare diseases

The GREGoR consortium provides foundational resources and substrates for the future of rare disease genomics.

Moez Dawood, Ben Heavner, Gabrielle C. Villard

Article Open Access 22 Oct 2025

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
Adam J. Grippin, Christiano Marconi, Steven H. Lin

Nature Biotechnology

Volume 43 Issue 10, October 2025

<https://www.nature.com/nbt/volumes/43/issues/10>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 15 Nov 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 11, November 2025

<https://www.nature.com/ng/volumes/57/issues/11>

Editorial 10 Nov 2025

[A call for 3D genomics submissions](#)

Nature Genetics has joined forces with *Nature Communications*, *Communications Biology* and *Scientific Reports* to create a Collection of papers on 3D genome organization. We reflect on the field and invite submissions addressing fundamental unsolved questions.

Comment 15 Oct 2025

[A Tribal data repository to advance Indigenous health and sovereignty](#)

We present the first federally funded Tribal data repository — the Data for Indigenous Implementations, Interventions, and Innovations Tribal Data Repository. This repository takes a revolutionary approach to data management by building space for researchers to engage with data from Indigenous groups under rigorous Tribal Nation governance and by prioritizing community data-sharing interests.

Matthew Z. Anderson, Krystal S. Tsosie, Joseph M. Yracheta

Perspective 31 Oct 2025

[Engaging migrants and immigrants in genetics research](#)

This Perspective examines the challenges to equitable participation of migrants and immigrants in genetics research and proposes inclusive, community-driven approaches to advance scientific discovery and overcome health disparities.

Mariana Valdez-Aguilar, Jamie L. Conklin, Dawit Shawel Abebe

Nature Human Behaviour

Volume 9 Issue 10, October 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/10>

[Reviewed earlier]

Nature Medicine

Volume 31 Issue 11, November 2025

<https://www.nature.com/nm/volumes/31/issues/11>

World View 27 Oct 2025

Shared responsibility and global progress in stem cell research

Stem cell science is at a pivotal moment, and decades of research have the potential to transform human health.

Valentina Greco

Research Briefing 15 Oct 2025

Rotavirus vaccine reduces gastroenteritis hospitalizations in Indian children

A multi-center, hospital-based observational study in India evaluated the effectiveness of Rotavac, a locally produced rotavirus vaccine, against laboratory-confirmed rotavirus gastroenteritis in children under 5 years of age. Vaccine effectiveness was stratified by age and viral genotype, and vaccine impact was assessed through comparisons of rotavirus positivity before and after Rotavac was introduced in the national immunization program.

Article Open Access 07 Oct 2025

Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020

In this multicentered observational study, Rotavac, an indigenous, monovalent, live, attenuated, oral rotavirus vaccine, had an adjusted vaccine efficacy of 54% and protected against severe gastroenteritis in Indian children during its rollout between 2016 and 2020.

Nayana P. Nair, Samarasimha N. Reddy, Mahima Mittal

Nature Reviews Drug Discovery

Volume 24 Issue 10, October 2025

<https://www.nature.com/nrd/volumes/24/issues/10>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 11, November 2025

<https://www.nature.com/nrg/volumes/26/issues/11>

Comment 31 Jul 2025

Integrating the genome and exposome for precision health in Kuwait

Extreme environmental conditions create stressors that can interact with genetic risk factors to influence health outcomes. In this Comment, the authors discuss their vision for a national programme in Kuwait that combines the genome and exposome to uncover gene–environment interactions and inform tailored disease-prevention strategies.

Hamad Ali, Barrak Alahmad, Fahd Al-Mulla

Comment 11 Sept 2025

Collaborating at the nexus of genomics, humanities, social science and stakeholders

Transdisciplinary collaboration fuels innovation and discovery. Meller et al. call for broader collaboration at the intersection of genomics, the humanities and social sciences, and wider societal stakeholders, to test new ways of working across disciplines and co-develop future research agendas.

Paul Meller, Peter Kilroy, Michael Dunn

Nature Reviews Immunology

Volume 25 Issue 10, October 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[Reviewed earlier]

New England Journal of Medicine Volume

Volume 393 No. 19 November 13, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 9 September 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 15 Nov 2025]

[No new digest content identified]

Pediatrics

Volume 156, Issue 5 November 2025

<https://publications.aap.org/pediatrics/issue/156/5>

From the American Academy of Pediatrics

Policy Statement

[Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement](#)

Committee on Infectious Diseases

Policy Statement

[Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement](#)

Committee on Infectious Diseases

PharmacoEconomics

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 15 Nov 2025)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 15 Nov 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 15 Nov 2025)

[The use of quarantine as an international travel measure during the COVID-19 pandemic: A comparative analysis of implementation and equity impacts in five “exemplar” countries](#)

Kelley Lee, Jane Williams, Yi-Chin Wu, Aysha Farwin, Youmi Kim, Sungkyu Lee, Natasha Howard, Salta Zhumatova Research Article | published 14 Nov 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0005457>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 15 Nov 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 15 Nov 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 15 Nov 2025]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 15 Nov 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

November 11, 2025 vol. 122 no. 45

<https://www.pnas.org/toc/pnas/122/45>

Special Feature

Structural Immunotherapy: Breakthroughs in Vaccine Development Fueled by Nanotechnology

Perspective

[Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics](#)

Michelle H. Teplensky, Julianna N. Bourgeois, [...] Chad A. Mirkin

Abstract

Structural immunotherapy relies on the structural features of immunotherapeutics in addition to component identity to influence biodistribution, intra- or extracellular localization, target engagement, and processing kinetics. This strategy is poised to redefine how immunotherapeutics mobilize immunity against disease and transform our ability to harness structure–function relationships to enhance clinical outcomes.

Political Sciences

Research Article November 5, 2025

Strategic analysis of dissent and self-censorship

Expressions of dissent against authority are an important feature of most societies, and efforts to suppress such expressions are common. Modern digital communications, social media, and Internet surveillance and censorship technologies are changing the ...

Joshua J. Daymude, Robert Axelrod and Stephanie Forrest

PNAS Nexus

Volume 4, Issue 9, September 2025

<https://academic.oup.com/pnasnexus/issue/4/9>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 4 - August 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 200 November 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/200/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

November 2025 Volume 292 Issue 2058

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 246 September 2025

<https://www.sciencedirect.com/journal/public-health/vol/246/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025
<https://journals.sagepub.com/toc/phrg/140/5-6>
[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 13, November 2025
<https://journals.sagepub.com/toc/QHR/current>
[Reviewed earlier]

Research Ethics

Volume 21 Issue 4, October 2025
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 15 Nov 2025]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>
Latest Articles
[No new digest content identified]

Risk Analysis

Volume 45, Issue 10 Pages: 2927-3330 October 2025
<https://onlinelibrary.wiley.com/toc/15396924/current>
[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 15 Nov 2025]
[No new digest content identified]

Royal Society Open Science

November 2025 Volume 12 Issue 11
<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 390| Issue 6774| 13 Nov 2025
<https://www.science.org/toc/science/current>

Feature

The pandemic next time

BY Jon Cohen

13 Nov 2025: 667-671

How President Donald Trump's administration has undermined efforts to develop vaccines and drugs for the next viral scourge

Science and Engineering Ethics

Volume 31, Issue 6 December 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-6>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 824| 12 Nov 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 15 Nov 2025]

[No new digest content identified]

Social Science & Medicine

Volume 386 December 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 15 Nov 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 67 September–October 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/67/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 11 Pages: 1145-1260 November 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 67 20 November 2025

<https://www.sciencedirect.com/journal/vaccine/vol/67/suppl/C>

Discussion Abstract only

[Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes](#)

Edwin J. Asturias, Lin H. Chen, Albert C. Shaw, Charlotte A. Moser, ... Noel T. Brewer
Article 127876

Discussion

[Overcoming vaccine cold chain challenges in Nepal's animal health sector: innovative strategies for effective immunisation](#)

Krishna Prasad Acharya, Sarita Phuyal, Bruno Silvester Lopes
Article 127857

Short communication Open access

[Tetanus and diphtheria vaccination coverage and electronic health record alerts for immigrants and refugees at three United States health systems, 2017–2023](#)

Abigail Steiner, Ann Settgaast, Malini DeSilva, Colleen Payton, ... Janine Young
Article 127881

Review article Abstract only

[Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review](#)

Chibueze Anosike, Iheomimichineke Mystery Ojiakor, Enyi Ifeoma Etiaba, Nkolika Pamela Uguru, ... Obinna Onwujekwe
Article 127853

Review article Open access

[Real-world vaccine effectiveness of typhoid conjugate vaccine in children and adolescents: a systematic review and meta-analysis](#)

Jonathan Hasian Haposan, Ajeng Viska Icanervilia, Emma Watts, Suci Ardini Widyaningsih, ... Julie E. Bines
Article 127872

Research article Abstract only

[Parental perceptions and willingness to pay for childhood vaccination experiences in China: a multi-city comprehensive evaluation study](#)

Bei Liu, Ninghua Huang, Yaqiong Liu, Xiyu Zhang, ... Fuqiang Cui
Article 127826

Research article Open access

[A global landscape of patenting activity in COVID-19 vaccines](#)

Eduardo Mercadante, Timo Minssen, Kenneth C. Shadlen, Esther van Zimmeren, ... Duncan Matthews
Article 127866

Research article Open access

The state of vaccine confidence among the general public in Eastern Europe and Central Asia

Rachel L. Eagan, Toni Claessens, Greet Hendrickx, Heidi J. Larson, Emilie Karafillakis
Article 127849

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 15 Nov 2025]

Open Access Article

Sustaining Local Production of Influenza Vaccines: A Global Study of Enabling Factors Among Vaccine Manufacturers

by Christopher Chadwick, Claudia Nannei, Erin Sparrow, William Ampofo, Antoine Flahault and Seth Berkley

Vaccines 2025, 13(11), 1160; <https://doi.org/10.3390/vaccines13111160> - 14 Nov 2025

Abstract

Background/Objectives: Local production is a global priority for increasing access to routine, outbreak, and pandemic vaccines and leads to a variety of direct and indirect benefits for countries. This study aimed to characterize the enabling environment for the sustainable production of influenza vaccines,

Open Access Article

Cost-Effectiveness Analysis of Universal Rotavirus Vaccination Schedules in Syria

by Mania Mershed, Razan Altarabishi, Rasha Mohamed, Lamia Abu ajaj, Dima Alrashee, Manar Kamel and Salah Al Awaidey

Vaccines 2025, 13(11), 1157; <https://doi.org/10.3390/vaccines13111157> - 12 Nov 2025

Abstract

Background: Rotavirus (RV) continues to be the leading cause of acute gastroenteritis (AGE) globally among children under five. National RV vaccination efforts have lowered morbidity and mortality. Vaccination is a key public health tool to alleviate this substantial burden of RV in middle- [\[...\]](#)

Value in Health

November 2025 Volume 28 Issue 11 p1601-1784

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

World Development

Volume 195 November 2025

<https://www.sciencedirect.com/journal/world-development/vol/195/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 15 Nov 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[No new digest content identified]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 15 Nov 2025]

[Filter: All articles]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 15 Nov 2025]

[Filter: All articles]

[Interventions to promote completion of human papilloma virus vaccination course in high-risk groups attending a London sexual health clinic](#)

George Budden, Sophie Mounouchos, Samantha Stancu

medRxiv 2025.11.12.25340109; doi: <https://doi.org/10.1101/2025.11.12.25340109>

[Third dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in absence of neutralizing antibodies](#)

Emily S.J. Edwards, Raffi Gugasyan, Nirupama Varese, Shir Sun, Jessica E. Canning, Ebony G. Blight, Pei M. Aui, Irene Boo, Stuart Turville, Anupriya Aggarwal, Samar Ojaimi, Julian J. Bosco, Stephanie Stojanovic, P. Mark Hogarth, Heidi E. Drummer, Scott J. Bornheimer, Robyn E. O’Hehir, Menno C. van Zelm

medRxiv 2025.11.09.25339598; doi: <https://doi.org/10.1101/2025.11.09.25339598>

[Private Choices in Public Health: Endogenous Behavioral Responses to Pandemic Risk](#)

J. Felipe Montano-Campos, Kyueun Lee, Blythe Adamson, Anirban Basu

medRxiv 2025.11.08.25339826; doi: <https://doi.org/10.1101/2025.11.08.25339826>

Abstract

Epidemic control depends not only on policy mandates but also on endogenous behavioral responses—how individuals adjust private preventive actions to evolving risk. Using over 1.1 million county-day observations from 1,206 U.S. counties, we integrate high-frequency mobility data with local COVID-19 mortality to estimate the semi-elasticity of preventive behavior to mortality-driven risk perception. Fixed-effects regressions exploit within-county temporal variation, controlling for day-of-week and month effects, county-specific linear trends, and public health policies. Behavioral elasticity evolved as the pandemic progressed. Early in the pandemic, mortality-driven risk perception had only a limited effect on behavior (3.1% reduction in mobility per additional death per 10,000 residents, 7-day lag), while shelter-in-place mandates drove large declines (−10.16%). As uncertainty declined and individuals learned about transmission risks, behavioral responsiveness strengthened markedly, with mobility falling 7.8% per additional death (7-day lag per 10,000)—indicating that risk-calibrated

adaptation supplanted broad precautionary withdrawal. By the post-vaccination stage, the mortality–mobility association was no longer significant, consistent with behavioral desensitization as perceived risk fell. To unpack the selective logic of prevention—when behavior most closely tracked perceived risk—we find that reductions were most pronounced in discretionary settings (–5.2% retail/recreation; –5.3% transit) but statistically insignificant in essential activities (–0.4% grocery/pharmacy) and low-risk outdoor spaces (–1.7% parks). Responsiveness weakened by roughly 0.5% per month, while shelter-in-place and mask mandates amplified mortality-driven behavioral responses by 2.8% and 4.7%. These findings highlight that voluntary, risk-responsive behavior—amplified by policy interventions—was pivotal to epidemic control.

Estimating the impact of vaccination and long-acting monoclonal antibodies for RSV epidemics across Hong Kong, Beijing, and Thailand: a modelling study

Kathy Leung, Ivan F. N. Hung, Chelsea L. Hansen, Carolyn A. Cohen, Jiayi Du, Hui-Ling Yen, Sophie A. Valkenburg, J. S. Malik Peiris, Cecile Viboud, Joseph T. Wu
medRxiv 2025.11.06.25339729; doi: <https://doi.org/10.1101/2025.11.06.25339729>

Research capacity and decolonization in Sub-Saharan Africa: a bibliometric analysis

Raita Tamaki, Yuki Furuse, Hirotake Mori, Kazuki Santa, Kazuki Shimizu, Hongxiang Wang, Kozo Watanabe, Ryo Komorizono, Samson Muuo Nzou, Evans Inyangla Amukoye, Elijah Maritim Songok, Dorothy Yeboah-Manu, Shingo Inoue, Satoshi Kaneko
medRxiv 2025.11.07.25339743; doi: <https://doi.org/10.1101/2025.11.07.25339743>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 15 Nov 2025]

Software Tool Article Open Access

REVISED - Scalable, open-access and multidisciplinary data integration pipeline for climate-sensitive diseases

[version 2; peer review: 1 approved, 1 not approved]

Abhishek Dasgupta

Abstract

Climate-sensitive infectious diseases pose an important challenge for human, animal and environmental health and it has been estimated that over half of known human pathogenic diseases can be aggravated by climate change. While climatic and weather conditions are important drivers of transmission of vector-borne diseases, socio-economic, behavioural, and land-use factors as well as the interactions among them impact transmission dynamics. Analysis of drivers of climate-sensitive diseases require rapid integration of interdisciplinary data to be jointly analysed with epidemiological (including genomic and clinical) data. Current tools for the integration of multiple data sources are often limited to one data type or rely on proprietary data and software. To address this gap, we develop a scalable and open-access pipeline for the integration of multiple spatio-temporal datasets that requires only the declaration of the country and temporal range and resolution of the study. The tool is locally deployable and can easily be integrated into existing climate-disease-modelling applications. We demonstrate the utility of the tool for dengue modelling in Vietnam where epidemiological data are legally required to remain local. We include a pipeline for bias correction of climate data to enhance their quality for downstream modelling tasks. The Dengue Advanced

Readiness Tools-Pipeline empowers users by simplifying complex download, correction, and aggregation steps, fostering data-driven discovery of relationships between infectious diseases and their drivers in space and time, and enhancing reproducibility in research. Additional modules and datasets can be added to the existing ones to make the pipeline extendable to use cases other than the ones presented here.

Plain language summary

Most human infectious diseases are affected by climate. Therefore, understanding how climate and other rapidly changing factors like land use, population behaviour, and socio-economic conditions influence the spread of these diseases requires combining many different types of data. However, tools that enable researchers and policy makers to bring together and use this data remain limited, difficult to use, or rely on software that is not freely available.

To address this gap, we developed a new, open-access software pipeline that helps users collect, clean, and prepare different types of data—such as weather, socio-economic, and health data—for analysis. The pipeline works with data across different locations and time periods, and only requires users to specify the country and timeframe they are interested in. It is designed to be easy to use and can be run on local computers, which is especially important in places where health data is not allowed to leave the country. We deployed the pipeline using data on dengue fever in Vietnam. By making the process simpler and more transparent, we hope to support faster and more reliable responses to climate-related health threats.

* * * *

Think Tanks

Brookings [to 15 Nov 2025]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [15 Nov 2025]

<https://www.cgdev.org/>

All Research

BRIEF

Tough Times, Tough Choices: Charting PEPFAR's Next Chapter While Safeguarding its Legacy

Rachel Bonnifield and Janeen Madan Keller

November 14, 2025

The Trump administration and key congressional lawmakers are shaping a new US government approach to the future of PEPFAR, alongside other global health programs like malaria and tuberculosis. We propose a differentiated three-track framework to operationalize a responsible PEPFAR transition while m...

CGD NOTE

Aid Isn't Fairy Dust

Charles Kenny

November 14, 2025

Long-term changes and the lessons of the past decade suggest rhetoric around what aid can accomplish needs to be dialed down. It is largely macroeconomically irrelevant in middle-income countries and has a weak record in leveraging or crowding in other resources. But aid still has a vital role to pl...

POLICY PAPER

Financing at a Crossroads: How the Global Fund Can Adapt to a Shrinking Aid Landscape

Janeen Madan Keller et al.

November 13, 2025

Amid widespread donor retrenchment, the Global Fund faces an era of austerity that threatens the sustainability of its donor-dependent, grant-based financing model. This paper models an alternative financial approach inspired by multilateral development funds such as the World Bank's International Development Bank (IDB). D...

Chatham House [to 15 Nov 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [15 Nov 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [15 Nov 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

McKinsey Global Institute [15 Nov 2025]

<https://www.mckinsey.com/mgi/overview>

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 15 Nov 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [15 Nov 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 15 Nov 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 15 Nov 2025]
<https://www.urban.org/research>
New Research Publications - Selected
No new digest content identified.

World Economic Forum [to 15 Nov 2025]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends 11/24/2025.**

Docket No. FDA-2017-D-6159 :: 21 pages

SUMMARY:

This guidance provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with our recommendations on the expedited development and review of these therapies, including as provided under section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3033 of the 21st Century Cures Act (Cures Act). Under section 506(g) of the FD&C Act, a regenerative medicine therapy can be designated as a regenerative advanced therapy if it meets certain criteria. FDA refers to such designation as “regenerative medicine advanced therapy” (RMAT) designation (see section III.C of this document). This guidance describes the expedited programs available to sponsors of regenerative medicine therapies for serious conditions, including those products designated as RMATs. To that end, the guidance provides information about the provisions in the Cures Act regarding the use of the accelerated approval pathway for regenerative medicine therapies that have been granted designation as an RMAT. Finally, the guidance describes considerations in the clinical development of regenerative medicine therapies and opportunities for sponsors of such products to interact with the Center for Biologics Evaluation and Research (CBER) review staff. As a general matter, this guidance addresses regenerative medicine therapies regulated by CBER as biological products under the FD&C Act, section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262), and applicable regulations.

Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends (11/24/2025).**

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01/2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on “Adaptive Clinical Trials” on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States)

Regulatory Chair: Dr. Christian Roes (EC, Europe)

Date of Step 2b: 25 June 2025 Status: Step 3

Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/23/2025. **Comment period ends 12/22/2025.**

Docket No. FDA-2025-D-0918

* * * *

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*